FTC Questions Apple News Over Alleged Bias Against Conservative Media 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
NEW YORK, Jan. 02, 2018 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The presentation is scheduled for Tuesday, January 9, 2018 at 2:00 pm PST.
The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease.
Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone: 212-923-3344
Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
Email: [email protected]
Phone: 212-213-0006
